At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 223 enrolled
Drug / intervention
Lyrica (pregabalin) +1 moredrug
Likely dose
Lyrica (pregabalin) 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Oct 20, 2011·Updated Jan 28, 2021
In Brief
A Phase 4 clinical trial evaluating Lyrica (pregabalin) and Placebo for Postherpetic Neuralgia ( PHN ). Completed, enrolled 223 participants across 22 sites.
Detailed Summary
To prove pregabalin is effective in relieving pain compared with placebo in subjects with postherpetic neuralgia (PHN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia ( PHN )
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartDec 2011
Primary CompletionJan 2014
TodayJul 2026
First PostedOct 20, 2011
Enrollment StartDec 1, 2011
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.7 years ago
Interventions
Lyrica (pregabalin)drug
Capsule, 300 mg/d, BID, 8 weeks treatment
Placebodrug
Capsule, 300 mg/d, BID, 8 weeks treatment